Synovial Sarcoma

Watchlist

(log in to enable)

Retrieved

2021-01-23

Source

Orphanet

Trials

—

Genes

SSX1, SSX2, SS18, BCL2, SHCBP1, VIM, TLE1, SYT1, CD38, SSX2B, SMARCB1, CTAG1A, CTNNB1, CTAG1B, TP53, ERBB2, EWSR1, KIT, CD99, EGFR, FZD10, SSX4, CD34, CCND1, BCOR, PROM1, CTSS, IGF2, MET, PDGFRA

SSX1, SSX2, SS18, BCL2, SHCBP1, VIM, TLE1, SYT1, CD38, SSX2B, SMARCB1, CTAG1A, CTNNB1, CTAG1B, TP53, ERBB2, EWSR1, KIT, CD99, EGFR, FZD10, SSX4, CD34, CCND1, BCOR, PROM1, CTSS, IGF2, MET, PDGFRA, TNF, EZH2, HEATR3, SS18L1, CDKN2A, VEGFA, IGF1R, IGF1, IL1B, MDM2, FOXM1, MMP2, MUC1, SOX2, HGF, STAT3, CDH1, PAX8, PRKAR1A, SPG7, CXCL12, SALL2, TGFB1, SOX10, IL17A, MAPK3, RASSF1, MAPK1, HPSE, TNFSF13B, BANF1, NME1, CXCR4, ABCB1, TRIM13, PAX3, OAT, NR1I3, PRAME, MKI67, YBX1, HDAC9, MMP9, ABCC1, VCAM1, H3P10, IL10, CD274, CRK, ATF2, CXADR, ELF3, ANKRD36B, CASR, ZNF654, F5, MIR206, CXADRP1, ETFA, HBA2, ARR3, HBG1, PWWP3B, MIR145, MIR10B, ERVW-4, GDF6, KLHL34, FRMPD2, EZR, STAT6, KCNH8, MIR761, AIMP2, NR4A3, SRC, MLLT10, LOC110806263, HMGA2, CCNB3, MIR155, SYCP1, TRBV20OR9-2, MIR92B, SYP, MIR495, ADAM17, TAGLN, TAP1, TAZ, TFPI, TLR3, MIR183, FRMPD2B, CDR3, DUX4, THAS, THBD, MIR17, HBHR, RNF19A, NCOA3, SSX3, CIB1, CXCL13, AHSA1, DYM, NES, NANS, FXYD5, PIAS4, SS18L2, PUF60, FLVCR1, SIRT2, PPRC1, CIC, NUPR1, SIRT1, POLDIP2, KCNH4, NGDN, MSLN, SLC12A9, KDM2B, KIDINS220, AXIN2, TNFSF13, SMUG1, LBH, VTCN1, BRD9, RASAL3, MBD2, USP6, REPS2, TSPYL2, VAMP3, ADIPOQ, GRAP2, PRM3, PDZD4, PIEZO1, MIB1, GINS1, SNAP23, ALB, SNAI1, ELK1, EP300, EPHB2, ERCC5, ERG, ESR1, F2, F2RL1, FGFR2, FOXO1, FOLH1, GAB1, GLB1, GLO1, GSK3B, HBA1, HBB, HBG2, HLA-A, HLA-C, HMGA1, ICAM1, IFNG, IL1A, IL5, IL6, CXCL8, IDO1, ENO2, EGR1, SMN2, DUSP6, ALK, APC, AQP8, FASLG, AQP5, AQP9, ATR, ATRX, BCL6, BCR, CFB, BIK, BMP6, CAV1, CD68, CDK4, CDK9, CDKN1A, CDKN1B, CDKN3, CLDN7, CRABP1, MAPK14, CSK, CTLA4, ACE, DECR1, INHA, ITGB2, KRT7, KRT19, PIK3CG, PLK1, PLS3, PMCH, MED1, MAPK8, ALDH1A1, PTEN, PTGS2, PTN, PTPN1, RAC1, RAD23B, RBBP8, RBP4, RPL34, S100A4, SAI1, TSPAN31, CX3CL1, SELE, SLC3A1, SLC6A4, SLC12A3, SMARCA1, SMARCA2, SMN1, PIK3CD, PIK3CB, PIK3CA, MSH3, LBR, MAGEA1, MAGEA4, MB, MCM7, MDK, MDM4, MIF, CXCL9, MLH1, MMP3, MMP14, MTHFR, PDGFRB, MUC4, MYCN, NEDD4, NFKB1, NKX2-2, TBC1D25, PAEP, PAX2, PAX7, PC, PCNA, PDCD1, MAP2K7

Drugs

(-)-trans-3-(5,6-dihydro-4H-pyrrolo[3,2,1-ij]quinolin-1yl)-4-(1H-indol-3-yl) pyrrolidine-2, 5-dione, (1-methyl-2-nitro-1H-imidazole-5-yl)methyl N,N'-bis(2-bromoethyl) diamidophosphate, 16-base single-stranded peptide nucleic acid oligonucleotide linked to a 7-amino acid peptide, 18-(p-(, 4-oxo-4H-chromene-2-carboxylic acid (2-(2-4-(2-(6,7-dimethoxy-3,4-dihydro-1H-isoquinolin-2-yl)-ethyl)-phenyl-2H-tetrazol-5-yl)-4,5-dimethoxy-phenyl)-amide, 7-ethyl-10-hydroxy-camptothecin, Anlotinib, Autologous CD4+ and CD8+ T cells transduced with a lentiviral vector encoding an affinity enhanced T cell receptor specific to MAGE-A4, Autologous CD4+ and CD8+ T cells transduced with lentiviral vector containing an affinity-enhanced T-cell receptor targeting the New York esophageal antigen-1, Brostallicin, Camsirubicin, Crenolanib besylate, Deforolimus, Doxorubicin hydrochloride (liposomal) ( DOXIL ), Doxorubicin(6-maleimidocaproyl)hydrazone, Fenretinide, Fibromun, Genetically modified serotype 5/3 adenovirus coding for granulocyte-macrophage colony-stimulating factor, Glucopyranosyl lipid A stable emulsion and recombinant New York oesophageal squamous cell carcinoma-1 protein (NY-ESO-1), Human/murine chimeric monoclonal antibody against endoglin, Ifosfamide ( HOLOXAN, IFEX ), Larotrectinib ( VITRAKVI ), Mammalian target of rapamcyin (mTOR) inhibitor, N-acetylsarcosyl-glycyl-L-valyl-D-allo-isoleucyl-L-threonyl-L-norvalyl-L-isoleucyl-L-arginyl-L-prolyl-N-ethylamide, Olaratumab ( LARTRUVO ), Ombrabulin, Paclitaxel ( TAXOL ), Palifosfamide, Propranolol hydrochloride ( HEMANGEOL ), Sindbis virus envelope pseudotyped lentiviral vector encoding New York oesophageal squamous cell carcinoma-1 protein, Trabectedin ( YONDELIS ), Vinorelbine tartrate, Yttrium (90Y)-DTPA-radiolabelled chimeric monoclonal antibody against frizzled homologue 10

Interested in hearing about new therapies?

Synovial sarcoma is an aggressive soft tissue sarcoma (see this term), occurring most commonly in adolescents and young adults (15 to 40 years), usually localized near the large joints of the extremities but also in the head and neck, mediastinum and viscera (lung, kidney etc), clinically presenting as a deep seated swelling or a painful mass often with an initial indolent course and is characterized by its local invasiveness and a propensity to metastasize. The origin of synovial sarcoma is likely from multipotent mesenchymal cells and not synovium (contrary to its name).